Neuroprotective/Neurotrophic Effect of Lexapro® in Patients With Posttraumatic Stress Disorder
NCT ID: NCT01008098
Last Updated: 2012-06-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
26 participants
INTERVENTIONAL
2008-11-30
2014-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. to evaluate the efficacy of escitalopram in treatment for post-traumatic stress disorder,
2. to find the structural changes of brain using magnetic resonance imaging and its association with the symptoms reduction, and
3. to look at the differences of brain imaging findings and symptoms changes according to genetic differences of brain-derived neurotrophic factor (a biological molecule facilitating neuronal growth in human).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Lexapro for the Treatment of Traumatic Brain Injury (TBI) Depression & Other Psychiatric Conditions
NCT01368432
Neuroimaging of Escitalopram in Autism Spectrum Disorder
NCT06826326
ERP N1 as a Treatment Predictor of Generalized Anxiety Disorder
NCT00613067
Progression Delaying Effect of Escitalopram in Alzheimer's Disease
NCT00702780
Escitalopram for the Treatment of Depression in Alzheimer's Disease
NCT01841125
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PTSD group
escitalopram (lexapro)
0 - 4 week: 10 mg escitalopram a day 5 - 8 week: 20 mg escitalopram a day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
escitalopram (lexapro)
0 - 4 week: 10 mg escitalopram a day 5 - 8 week: 20 mg escitalopram a day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* PTSD diagnosed by SCID-IV
Exclusion Criteria
* Neurologic disease (eg., epilepsy, infarct, multiple sclerosis, brain tumor)
* Any other axis I psychiatric disorder diagnosed by SCID-IV
* Borderline personality disorder or antisocial personality disorder
* IQ below 80
* Any contraindication to MRI scan
* Any current psychotropic medication
* Unstable medical illness or severe abnormality in laboratory test at screening assessment
* Women who are pregnant, breastfeeding, or planning pregnancy
* Any contraindications to drug used in the study (e.g., allergy, intolerance, etc.)
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Seoul National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
In Kyoon Lyoo, MD, PhD, MMS
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
In Kyoon Lyoo, MD, PhD, MMS
Role: PRINCIPAL_INVESTIGATOR
Seoul National University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul National University Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KR_12661A
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.